1)日本脳卒中学会 脳卒中ガイドライン[追補2017]委員会(編):脳卒中治療ガイドライン2015[追補2017],2017
2)日本透析医学会(編):血液透析患者における心血管合併症の評価と治療に関するガイドライン.透析会誌44:337-425, 2011
3)日本透析医学会 統計調査委員会:わが国の慢性透析療法の現況(2017年12月31日現在).透析会誌51:699-766, 2018
4)Iseki K, et al:Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int 44:1086-1090, 1993
5)三瀬直文,他:メシル酸ナファモスタットによる重篤な薬剤アレルギーの検討.透析会誌37:65-70, 2004
6)Anderson CS, et al:Intensive blood pressure reduction in acute cerebral haemorrhage trial(INTERACT);A randomised pilot trial. Lancet Neurol 7:391-399, 2008
7)Rose JC, Mayer SA:Optimizing blood pressure in neurological emergencies. Neurocrit Care 1:287-299, 2004
8)Onoyama K, et al:Incidence of strokes and its prognosis in patients on maintenance hemodialysis. Jpn Heart J 27:685-691, 1986
9)Osaki Y, et al:Post-stroke hypertension correlates with neurologic recovery in patients with acute ischemic stroke. Hypertens Res 21:169-173, 1998
10)International Stroke Trial Collaborative Group:The International Stroke Trial(IST);A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 349:1569-1581, 1997
11)日本脳卒中学会(編):rt-PA(アルテプラーゼ)静注療法適正治療指針(第2版),2012
12)豊田一則:維持透析患者における脳梗塞急性期のエダラボン治療.Geriatric Medicine 41:673-679, 2003
13)Chan KE, et al:Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J Am Soc Nephrol 20:2223-2233, 2009